论文信息 - Safety and Efficacy of the PI3Kδ Inhibitor Zandelisib in Combination with the BTK Inhibitor Zanubrutinib in Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) or Mantle Cell Lymphoma (MCL) - 字舞流文

Safety and Efficacy of the PI3Kδ Inhibitor Zandelisib in Combination with the BTK Inhibitor Zanubrutinib in Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) or Mantle Cell Lymphoma (MCL)

I. Lossos | A. Zelenetz | F. Awan | R. Ghalie | A. Asch | F. Samaniego | C. Diefenbach | V. Kenkre | D. Jagadeesh | Abhijeet Kumar | J. Soumerai | H. Salman | M. Tsai | Lu Miao